Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)

Martin Faehling,Christian Schumann,Petros Christopoulos,Petra Hoffknecht,Jürgen Alt,Marlitt Horn,Stephan Eisenmann,Anke Schlenska-Lange,Philipp Schütt,Felix Steger,Wolfgang M Brückl,Daniel C Christoph

Lung Cancer（2020）

引用 35|浏览34

暂无评分

摘要

•Durvalumab after chemoradiotherapy is safe and effective in clinical practice.•Survival in the German EAP was similar to the PACIFIC trial.•Patients with oligometastatic or autoimmune disease might benefit from durvalumab.•PD-L1-negative and PD-L1 positive patients have similar survival.

查看译文

关键词

AE,CI,CRT,CTCAE 5.0,EAP,ECOG,EMA,HR,IASLC,LCNEC,NA,NSCLC,NOS,NR,NSCLC,OS,PD-L1,PFS,PY

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要